Prothena Corporation plc (PRTA) |
24.77 -0.39 (-1.55%) 03-28 16:00 |
Open: | 25.25 |
High: | 25.34 |
Low: | 24.29 |
Volume: | 773,086 |
Market Cap: | 1,331(M) |
PE Ratio: | -8.97 |
Exchange: | NASDAQ Global Select |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 31.03 |
Resistance 1: | 28.46 |
Pivot price: | 26.28 |
Support 1: | 24.29 |
Support 2: | 20.21 |
52w High: | 79.65 |
52w Low: | 24.285 |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
EPS | -190110000.000 |
Book Value | 0.000 |
PEG Ratio | -0.15 |
Gross Profit | -451.818 |
Profit Margin (%) | -160.91 |
Operating Margin (%) | -24.00 |
Return on Assets (ttm) | 846.5 |
Return on Equity (ttm) | -16.4 |
Wed, 27 Mar 2024
Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY - Yahoo Movies Canada
Mon, 25 Mar 2024
SG Americas Securities LLC Has $4.94 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Mon, 25 Mar 2024
SG Americas Securities LLC Acquires 43363 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Fri, 22 Mar 2024
Prothena Corporation plc (NASDAQ:PRTA) Shares Could Be 36% Below Their Intrinsic Value Estimate - Yahoo Movies Canada
Fri, 23 Feb 2024
Prothena: Alzheimer's Data Update In 2024 Could Move The Needle (NASDAQ:PRTA) - Seeking Alpha
Fri, 16 Feb 2024
Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript - Yahoo Finance
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |